AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

JPMorgan raises target for AbbVie stock to USD 300

Analyst upgrade AI-generated analysis

πŸ“ˆ JPMorgan raised its price target for AbbVie to USD 300 from USD 285 on October 8, 2026.

πŸ’° Second-quarter revenue increased 10.20% year-over-year to reach USD 16.99 billion.

πŸ“‰ Humira revenue declined 35.90% to USD 756 million as the company transitions its portfolio.

πŸš€ Newer medicines successfully offset legacy declines, driving total sales growth.

πŸ’΅ Adjusted earnings per share rose to USD 3.65 compared to USD 2.97 in the prior-year quarter.

πŸ“… Third-quarter results are scheduled for release on October 30, 2026.

πŸ’Έ The company is guiding for Q3 adjusted EPS between USD 3.84 and USD 3.88.

🏦 Market capitalization stood at USD 504.4 billion as of October 16, 2026.

πŸ“Š Stock price was EUR 254.35 on October 19, 2026, near the upper end of the 52-week range.

πŸ’° A dividend payment of USD 1.73 per share is scheduled for November 16, 2026.

Bullish Signals
  • JPMorgan raised its price target to USD 300 from USD 285, signaling strong confidence in the company's trajectory.
  • Second-quarter revenue grew 10.20% year-over-year to USD 16.99 billion, demonstrating robust top-line performance.
  • Adjusted earnings per share increased significantly to USD 3.65 from USD 2.97 in the prior-year quarter.
  • Newer medicines successfully compensated for legacy declines, proving the strength of the company's pipeline.
  • The stock is trading near the upper end of its 52-week range at EUR 254.35, reflecting positive market sentiment.
Risk Factors
  • Humira revenue fell 35.90% to USD 756 million, highlighting the ongoing challenge of patent expiration and portfolio transition.
  • The company faces a higher price target hurdle of USD 300 following the analyst upgrade, requiring continued strong execution.
Full Analysis
JPMorgan raised its price target for AbbVie Inc. (ABBV) to USD 300 on October 8, 2026, marking a significant increase from the previous target of USD 285. This bullish analyst action follows the company's strong second-quarter financial performance, where revenue surged 10.20% year-over-year to reach USD 16.99 billion. The stock was trading at EUR 254.35 on October 19, 2026, positioning it near the upper end of its 52-week range. The company's financial results highlight a strategic transition period where legacy franchise growth is being offset by declines in key products like Humira, which saw revenue drop 35.90% to USD 756 million. Despite this specific decline, newer medicines successfully drove total sales higher, validating the importance of the company's pipeline for future valuation. Adjusted earnings per share climbed to USD 3.65, a substantial increase from USD 2.97 in the prior-year quarter. Looking ahead, AbbVie is guiding for third-quarter adjusted earnings per share between USD 3.84 and USD 3.88, with results scheduled for release on October 30, 2026. Investors will also be watching for the upcoming dividend payment of USD 1.73 per share set for November 16, 2026. The market capitalization stands at approximately USD 504.4 billion as of mid-October.